default author photo

Xiaoyan Yan

Peking University - Clinical Research Institute

Beijing

China

SCHOLARLY PAPERS

2

DOWNLOADS

360

TOTAL CITATIONS

7

Scholarly Papers (2)

1.

Venetoclax Plus “3+7” Chemotherapy As the First-Line Therapy for Adult Patients With Acute Myeloid Leukemia

Number of pages: 47 Posted: 31 Jan 2022
Zhejiang University - Department of Hematology, Zhejiang University - Department of Hematology, affiliation not provided to SSRN, Zhejiang University - Bone Marrow Transplantation Center, Zhejiang University - Department of Hematology, Zhejiang University - Department of Hematology, Zhejiang University - Department of Hematology, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Ningbo University, Zhejiang University - Department of Hematology, affiliation not provided to SSRN, Zhejiang University - Department of Hematology, affiliation not provided to SSRN, affiliation not provided to SSRN, Zhejiang University - Department of Hematology, Zhejiang University - Department of Hematology, affiliation not provided to SSRN, Zhejiang University - Zhejiang Provincial Key Laboratory of Pancreatic Disease, Peking University - Clinical Research Institute, Zhejiang University - Department of Hematology and Zhejiang University - Department of Hematology
Downloads 227 (336,244)

Abstract:

Loading...

Acute myeloid leukemia, Venetoclax, Response, Safety.

2.

Treatment with Human Umbilical Cord-Derived Mesenchymal Stem Cells for Severe COVID-19 Patients with Lung Damage: A Randomised, Double-Blind, Placebo‑Controlled Phase 2 Trial

Number of pages: 36 Posted: 14 Oct 2020
Government of the People's Republic of China - Treatment and Research Center for Infectious Diseases, Second Military Medical University - Department of Respiratory, Wuhan Huoshenshan Hospital, Peking University - Clinical Research Institute, General Hospital of Central Theater Command - Department of Infectious Disease, Government of the People's Republic of China - Treatment and Research Center for Infectious Diseases, Government of the People's Republic of China - Treatment and Research Center for Infectious Diseases, Government of the People's Republic of China - Treatment and Research Center for Infectious Diseases, Government of the People's Republic of China - Treatment and Research Center for Infectious Diseases, Government of the People's Republic of China - Fifth Medical Center of Chinese PLA General Hospital, Government of the People's Republic of China - Treatment and Research Center for Infectious Diseases, Chinese PLA General - Department of Infectious Diseases, Government of the People's Republic of China - Treatment and Research Center for Infectious Diseases, Wuhan Huoshenshan Hospital, Huazhong University of Science and Technology - Department of Hematology, Wuhan Huoshenshan Hospital, Government of the People's Republic of China - Treatment and Research Center for Infectious Diseases, Government of the People's Republic of China - Department of Endocrinology and Metabolism, Huazhong University of Science and Technology - Department of Radiology, Wuhan Huoshenshan Hospital, General Hospital of Central Theater Command - Department of Infectious Disease, Government of the People's Republic of China - Treatment and Research Center for Infectious Diseases, Government of the People's Republic of China - General Hospital of Beijing Military Region, Chinese PLA General Hospital - Department of Infectious Diseases, Peking University - Clinical Research Institute, Wuhan Huoshenshan Hospital, Wuhan Huoshenshan Hospital, Wuhan Huoshenshan Hospital, Peking University - Clinical Research Institute, Government of the People's Republic of China - Department of Gastroenterology and Government of the People's Republic of China - Treatment and Research Center for Infectious Diseases
Downloads 133 (558,171)
Citation 7

Abstract:

Loading...

COVID-19, Mesenchymal stem cells, Randomised controlled trial